New York, N.Y. (February 18, 2025) - Validose, a 10XBeta Venture Studio portfolio company pioneering precision medication delivery, announced today the successful close of a $2 million pre-seed funding round. The round was led by Peter Bauer’s Family Office as part of its Technology for Humanity strategy, 10XBeta, and Interstate Fusion Ventures; several angel investors participated. Validose addresses patient non-adherence in clinical trials—one of the most persistent challenges in drug development—with an innovative approach linking behavior modeling with remote data capture. This round of funding will be used to finalize the development of the company’s ophthalmic solution, a smart-dose eye-dropper, which will be launched in Q2 2025.

The Validose platform uses an agile dose device, coupled with real-time data delivered to clinicians, to leverage a suite of behavioral prompts that can drive patient behavior. The technology is designed to support diverse therapies, including the ophthalmic smart-dose solution, as well as additional form factors, including a CNS-focused nasal spray device and pill delivery system. The platform delivers objective, precise, and secure real-time adherence data while providing personalized behavioral support to improve patient compliance.

By tackling the critical issue of non-adherence—which contributes to the failure of 30% of drug clinical trials—Validsode aims to dramatically improve clinical trial outcomes and reduce inefficiency in the drug discovery process. Moreover, the company’s solution is especially valuable in trials where non-adherence has high-stakes adverse health effects and patient recruitment poses challenges.

“Validose is addressing a critical challenge in drug development: clinical trial failures due to patient non-adherence,” said Paul McGrath, CEO of Validose. “Non-adherence significantly raises costs and delays healthcare innovation. While existing solutions offer delayed or passive adherence monitoring, Validose has introduced a proactive, real-time adherence platform that reshapes patient behavior, enhances trial oversight, and accelerates decision-making. We are grateful to  our investors for their support as we aim to address a critical healthcare industry challenge, transform clinical trials, and improve drug development.”

Validose’s approach represents a significant departure from the current market standard, in which non-adherence is poorly tracked or ignored. Currently prevalent approaches require patients to log their adherence in written journal entries or tracking apps, which leads to inconsistent and inaccurate reporting. Unlike traditional systems, Validose integrates with standard drug packaging, providing patients with personalized engagement tools and empowering trial coordinators with actionable insights for timely interventions.

“At 10XBeta, we are committed to bringing together founders, capital, investors, and talent to launch MedTech solutions that tackle the most significant challenges facing the healthcare industry,” said Marcel Botha, CEO and Co-Founder of 10XBeta. “Patient non-adherence in clinical trials has long been a costly and time-consuming pain point, leading to failed or delayed drug discovery. We are proud to support Validose in developing cutting-edge technology with the potential to drive significant improvements in clinical trials.” 

The Validose platform includes a Dose Exoskeleton—a multi-sensor, adaptable attachment that records adherence metrics across various medication forms. The exoskeleton can be used with nasal spray, ophthalmic drops, and other therapeutic applications, enabling precise tracking and scalability across multiple drug forms. Validose also provides a Patient Portal, which offers personalized dose reminders, real-time messaging, and behavioral coaching, promoting active patient compliance with motivational prompts to maintain engagement. A Clinician Dashboard provides trial coordinators with real-time adherence insights, enabling them to make timely interventions and optimize trial outcomes through secure, immediate access to patient data. 

About Validose

Validose is a healthcare technology company revolutionizing medication adherence and precision dosing. A 10XBeta portfolio company, Validose leverages cutting-edge engineering to create solutions that ensure secure, real-time dosing and patient engagement, transforming outcomes in clinical trials and therapeutic care. For more information, visit https://www.validose.com/.

About 10XBeta

10Xbeta is a MedTech Venture Studio based in the Brooklyn Navy Yard, New York. By streamlining medical device development and focusing on underserved healthcare needs, 10XBeta delivers impactful solutions that reduce time, cost, and risk. Through strategic public-private partnerships and a commitment to U.S.-based manufacturing, 10XBeta redefines how medical technologies are developed, tested, and brought to market. Their portfolio includes companies developing groundbreaking solutions in disability health, female health, and veteran care, and more, with a focus on creating a healthier future for all. For more information, visit https://www.10xbeta.com/.